Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Two-Dimensional Infrared Spectroscopy Offers Clues into Amyloid Disease Mechanisms

By BiotechDaily International staff writers
Posted on 04 Aug 2014
Image: Schematic of the intermediate structure in the aggregation pathway of amylin (Photo courtesy of Zhang, Buchanan, Zanni, Biomedical Spectroscopy and Imaging).
Image: Schematic of the intermediate structure in the aggregation pathway of amylin (Photo courtesy of Zhang, Buchanan, Zanni, Biomedical Spectroscopy and Imaging).
Amyloid diseases, such as type 2 diabetes, cataracts, Alzheimer’s disease, and the spongiform encephalopathies, all share the common characteristic that proteins aggregate into long fibers that then form plaques. However, recent in vitro research has demonstrated that neither the amylin monomer precursors nor the plaques themselves are very toxic. New data revealed by using two-dimensional infrared (2D IR) spectroscopy shows an intermediate structure during the amylin aggregation pathway that may clarify toxicity, offering new strategies for interventions.

The findings were published in the online July 1, 2014, in the journal Biomedical Spectroscopy and Imaging. “Figuring out how and why amyloid plaques form is exceedingly difficult, because one needs to follow the atomic shapes of the protein molecules as they assemble. Most tools in biology give either shapes or motions, but not both. We have been developing a new spectroscopic tool, called two-dimensional infrared spectroscopy, which can monitor the plaques as they form in a test tube,” said lead investigator Martin T. Zanni, PhD, from the department of chemistry at the University of Wisconsin-Madison (USA).

The researchers utilized this new technology to study the amyloid protein associated with type 2 diabetes. Isotope labeling was used to measure the secondary structure content of individual residues. By following many 2D IR spectra from one particular region (known as the FGAIL region) over several hours, they were able to visualize the amylin as it progressed from monomers to fibers.

“We learned that, prior to making the plaques, the proteins first assemble into an unexpected and intriguing intermediate and organized structure,” commented Dr. Zanni. The proteins undergo a transition from disordered coil (in the monomer), to ordered β-sheet (in the oligomer) to disordered structure again (in the fiber).

These findings help to elucidate the physics of the aggregation process, the chemistry of amyloid inhibitors, and the biology of type 2 diabetes, as well as elucidate earlier contradictory data.

The scientists suggest that differences between species in their capacity to develop type 2 diabetes may be related to the capacity to form these intermediate amylin structures. That may be why humans develop the disease while dogs and rats do not. “I am not encouraging us to begin engineering our DNA to match that of rats, but our findings may help to develop plaque inhibitors or hormone replacement therapies for people suffering from type 2 diabetes, because we know the structure we want to avoid,” said Dr. Zanni. He added that mutations in the FGAIL region may inhibit fiber formation by interfering with the formation of these intermediates.

Related Links:

University of Wisconsin-Madison



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: To adhere to catheters and start urinary tract infections, bacteria extend microscopic fibers with sticky proteins at their ends. Researchers have developed a vaccine that blocks the EbpA protein, visible as a white bulge above, and stops infections in mice (Photo courtesy of Dr. John Heuser, Washington University School of Medicine).

Blocking Binding of Bacteria to Fibrinogen Prevents Biofilm Formation and Catheter-Associated Bladder Infection in Mice

A team of molecular microbiologists has identified and targeted a critical step in biofilm formation and developed a vaccine that prevents catheter-associated urinary tract infections in mice.... Read more

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.